|
US5658920A
(en)
|
1991-01-16 |
1997-08-19 |
Daiichi Pharmaceutical Co., Ltd. |
Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
|
|
US6504029B1
(en)
|
1995-04-10 |
2003-01-07 |
Daiichi Pharmaceutical Co., Ltd. |
Condensed-hexacyclic compounds and a process therefor
|
|
EP0841924B1
(en)
|
1995-08-02 |
2002-10-02 |
Newcastle University Ventures Limited |
Benzimidazole compounds
|
|
DE69707860T2
(de)
|
1996-04-26 |
2002-04-11 |
Daiichi Pharmaceutical Co., Ltd. |
Verfahren zur herstellung von tetrahydroindolizinen
|
|
TW409058B
(en)
|
1996-06-06 |
2000-10-21 |
Daiichi Seiyaku Co |
Method for preparation of a drug complex
|
|
TW527183B
(en)
|
1996-06-06 |
2003-04-11 |
Daiichi Seiyaku Co |
Drug complex
|
|
IN189180B
(enExample)
|
1997-07-09 |
2003-01-04 |
Chong Kun Dang Corp |
|
|
MY132496A
(en)
|
1998-05-11 |
2007-10-31 |
Vertex Pharma |
Inhibitors of p38
|
|
EA003398B1
(ru)
|
1998-05-22 |
2003-04-24 |
Дайити Фармасьютикал Ко., Лтд. |
Лекарственный комплекс c полимерным носителем
|
|
CN1191093C
(zh)
|
1998-10-30 |
2005-03-02 |
第一制药株式会社 |
Dds化合物及其测定方法
|
|
IL142917A0
(en)
|
1998-11-03 |
2002-04-21 |
Basf Ag |
Substituted 2-phenylbenzimidazoles, the production thereof and their use
|
|
US6495541B1
(en)
|
1999-01-11 |
2002-12-17 |
Agouron Pharmaceuticals, Inc. |
Tricyclic inhibitors of poly(ADP-ribose) polymerases
|
|
DE19920936A1
(de)
|
1999-05-07 |
2000-11-09 |
Basf Ag |
Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
|
|
ECSP003637A
(es)
|
1999-08-31 |
2002-03-25 |
Agouron Pharma |
Inhibidores triciclicos de poli (adp-ribosa) polimerasas
|
|
US6699876B2
(en)
|
1999-11-18 |
2004-03-02 |
Les Laboratoires Servier |
Camptothecin analogue compounds
|
|
CA2396513A1
(en)
|
1999-12-13 |
2001-06-14 |
Yanzhi Zhang |
Pseudomycin phosphate prodrugs
|
|
US6844318B2
(en)
*
|
2000-03-15 |
2005-01-18 |
Bristol Myers Squibb Pharma Company |
Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
|
|
AU2001271037A1
(en)
|
2000-07-13 |
2002-01-30 |
Daiichi Pharmaceutical Co., Ltd. |
Pharmaceutical compositions containing dds compounds
|
|
US7151102B2
(en)
|
2000-10-30 |
2006-12-19 |
Kudos Pharmaceuticals Limited |
Phthalazinone derivatives
|
|
US6441163B1
(en)
*
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
US7771727B2
(en)
|
2002-03-01 |
2010-08-10 |
The Administrators Of The Tulane Educational Fund |
Conjugates of therapeutic or cytotoxic agents and biologically active peptides
|
|
GEP20074230B
(en)
|
2002-03-20 |
2007-11-12 |
Bristol Myers Squibb Co |
Phosphate prodrugs of fluorooxindoles
|
|
DE60335359D1
(de)
|
2002-04-30 |
2011-01-27 |
Kudos Pharm Ltd |
Phthalazinonderivate
|
|
US7449464B2
(en)
|
2003-03-12 |
2008-11-11 |
Kudos Pharmaceuticals Limited |
Phthalazinone derivatives
|
|
CA2520997A1
(en)
|
2003-03-31 |
2004-10-14 |
Stacie Sara Canan-Koch |
Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
|
|
CN1816356A
(zh)
|
2003-05-14 |
2006-08-09 |
免疫原公司 |
药物缀合物组合物
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
|
MXPA05011811A
(es)
|
2003-05-20 |
2006-02-17 |
Immunogen Inc |
Agentes citotoxicos mejorados que comprenden nuevos maitansinoides.
|
|
US7531530B2
(en)
|
2003-07-25 |
2009-05-12 |
Cancer Research Technology Limited |
Therapeutic compounds
|
|
GB0317466D0
(en)
|
2003-07-25 |
2003-08-27 |
Univ Sheffield |
Use
|
|
PL2305221T3
(pl)
|
2003-12-01 |
2015-11-30 |
Kudos Pharm Ltd |
Inhibitory naprawy uszkodzeń DNA w leczeniu raka
|
|
CA2556752C
(en)
|
2004-02-23 |
2016-02-02 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
CN101098854B
(zh)
|
2004-07-23 |
2012-12-05 |
恩多塞特公司 |
二价连接体及其轭合物
|
|
PT1794163E
(pt)
|
2004-09-22 |
2010-03-01 |
Pfizer |
Método para a preparação de inibidores de poli(adpribose)- polimerases
|
|
MX2007003314A
(es)
|
2004-09-22 |
2007-08-06 |
Pfizer |
Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas.
|
|
ATE551345T1
(de)
|
2004-09-22 |
2012-04-15 |
Pfizer |
Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on
|
|
US8603483B2
(en)
|
2004-12-09 |
2013-12-10 |
Janssen Biotech, Inc. |
Anti-integrin immunoconjugates, methods and uses
|
|
WO2006078816A2
(en)
|
2005-01-18 |
2006-07-27 |
The Board Of Governors For Higher Education |
Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
|
|
US7301019B2
(en)
|
2005-01-21 |
2007-11-27 |
Immunogen, Inc. |
Method for the preparation of maytansinoid esters
|
|
ES2503719T3
(es)
|
2005-02-11 |
2014-10-07 |
Immunogen, Inc. |
Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
|
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
KR20070120156A
(ko)
|
2005-04-15 |
2007-12-21 |
이뮤노젠 아이엔씨 |
종양에서 이종 또는 혼성 세포 집단의 제거 방법
|
|
CA3000520C
(en)
|
2005-08-24 |
2023-04-04 |
Immunogen, Inc. |
Process for preparing antibody maytansinoid conjugates
|
|
JP5227796B2
(ja)
|
2005-09-29 |
2013-07-03 |
アボット・ラボラトリーズ |
２位においてフェニルによって置換された１ｈ−ベンズイミダゾール−４−カルボキサミドは強力なｐａｒｐ阻害薬である
|
|
EP1945647B9
(en)
|
2005-11-08 |
2012-11-14 |
Immunogen, Inc. |
Processes for preparation of maytansinol
|
|
EP1976515A2
(en)
|
2006-01-17 |
2008-10-08 |
Abbott Laboratories |
Combination therapy with parp inhibitors
|
|
BRPI0710407A2
(pt)
|
2006-05-04 |
2012-04-17 |
Genentech Inc |
poliptìdeos, peixes-zebra transgênicos, modelos de sistemas, métodos de identificação de compostos, de identificação de agentes, métodos de tratamento de disfunções relativas a apoptose, método de identificação de agentes de prevenção ou redução da apoptose, composição de aumento da apoptose, composições de redução ou prevenção de apoptose, composição de apoptose, método de detecção, kits e artigo industrializado
|
|
UY30639A1
(es)
|
2006-10-17 |
2008-05-31 |
Kudos Pharm Ltd |
Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
|
|
JP4611444B2
(ja)
|
2007-01-10 |
2011-01-12 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
|
|
WO2008114114A2
(en)
|
2007-03-16 |
2008-09-25 |
Pfizer Products Inc. |
Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
|
|
CN101784565B
(zh)
|
2007-06-25 |
2014-12-10 |
恩多塞特公司 |
含有亲水性间隔区接头的共轭物
|
|
US8067613B2
(en)
|
2007-07-16 |
2011-11-29 |
Abbott Laboratories |
Benzimidazole poly(ADP ribose)polymerase inhibitors
|
|
PL2187965T3
(pl)
|
2007-08-17 |
2020-05-18 |
Purdue Research Foundation |
Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
|
|
SG189817A1
(en)
|
2008-04-30 |
2013-05-31 |
Immunogen Inc |
Potent conjugates and hydrophilic linkers
|
|
PE20100083A1
(es)
|
2008-06-05 |
2010-02-17 |
Janssen Pharmaceutica Nv |
Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
|
|
US20160095939A1
(en)
|
2014-10-07 |
2016-04-07 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
|
SG10201810743WA
(en)
|
2009-06-03 |
2018-12-28 |
Immunogen Inc |
Conjugation methods
|
|
WO2011066418A1
(en)
|
2009-11-25 |
2011-06-03 |
Academia Sinica |
The tumor-selective anti-cancer prodrug bqc-g
|
|
EP4166558A1
(en)
|
2010-02-12 |
2023-04-19 |
Pfizer Inc. |
Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
|
|
CA2790577A1
(en)
|
2010-02-25 |
2011-09-01 |
Purdue Research Foundation |
Psma binding ligand-linker conjugates and methods for using
|
|
SG184324A1
(en)
|
2010-03-31 |
2012-11-29 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
|
ES2584381T3
(es)
|
2010-05-05 |
2016-09-27 |
Prolynx Llc |
Liberación controlada de compuestos activos desde conjugados macromoleculares
|
|
EP4321168A3
(en)
|
2010-07-13 |
2024-04-24 |
Yale University, Inc. |
Environmentally sensitive compositions
|
|
AU2011289279B2
(en)
|
2010-08-13 |
2016-11-03 |
University Of Rhode Island Board Of Trustees |
Liposome compositions and methods of use thereof
|
|
AU2011323316B2
(en)
|
2010-11-03 |
2016-02-25 |
Immunogen, Inc. |
Cytotoxic agents comprising new ansamitocin derivatives
|
|
ME03353B
(me)
|
2011-03-29 |
2019-10-20 |
Immunogen Inc |
Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
|
|
MY171008A
(en)
|
2011-03-29 |
2019-09-23 |
Immunogen Inc |
Preparation of maytansinoid antibody conjugates by a one-step process
|
|
BR112014009050B1
(pt)
|
2011-10-14 |
2022-06-21 |
Medimmune Limited |
Conjugado anticorpo-fármaco de pirrolbenzodiazepinas, composição farmacêutica que compreende o mesmo, bem como compostos de pirrolbenzodiazepinas
|
|
ES2773710T3
(es)
|
2012-10-11 |
2020-07-14 |
Daiichi Sankyo Co Ltd |
Enlazadores para conjugados de anticuerpo - fármaco
|
|
WO2014061277A1
(ja)
|
2012-10-19 |
2014-04-24 |
第一三共株式会社 |
親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
|
|
EP2911701A4
(en)
|
2012-10-23 |
2016-06-08 |
Univ Johns Hopkins |
Novel self-assembling drug amphiphiles and methods for synthesis and application
|
|
US9919059B2
(en)
|
2012-12-10 |
2018-03-20 |
Massachusetts Institute Of Technology |
Multistage nanoparticle drug delivery system for the treatment of solid tumors
|
|
EP2927227A4
(en)
|
2013-01-03 |
2015-12-30 |
Celltrion Inc |
ANTIBODY CONCENTRATOR REMEDY CONJUGATE, METHOD OF MANUFACTURING THEREOF, AND ANTIBODY TOGETHER THEREWITH
|
|
EP3566750A3
(en)
|
2013-02-28 |
2020-04-08 |
ImmunoGen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
|
KR102442906B1
(ko)
|
2013-12-19 |
2022-09-14 |
씨젠 인크. |
표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커
|
|
CN105917007A
(zh)
|
2014-01-16 |
2016-08-31 |
克洛维斯肿瘤有限公司 |
Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途
|
|
HUE045065T2
(hu)
|
2014-01-31 |
2019-12-30 |
Novartis Ag |
TIM-3 antitest molekulák és felhasználásaik
|
|
JP2017114763A
(ja)
|
2014-03-26 |
2017-06-29 |
第一三共株式会社 |
抗ｃｄ９８抗体−薬物コンジュゲート
|
|
KR102445502B1
(ko)
|
2014-04-10 |
2022-09-21 |
다이이찌 산쿄 가부시키가이샤 |
항her3 항체-약물 콘주게이트
|
|
EP3130608B1
(en)
|
2014-04-10 |
2019-09-04 |
Daiichi Sankyo Co., Ltd. |
(anti-her2 antibody)-drug conjugate
|
|
WO2016004043A1
(en)
|
2014-06-30 |
2016-01-07 |
Blend Therapeutics, Inc. |
Targeted conjugates and particles and formulations thereof
|
|
AU2015305696B2
(en)
|
2014-08-22 |
2019-08-29 |
Pharma& Schweiz Gmbh |
High dosage strength tablets of rucaparib
|
|
JP6214790B2
(ja)
|
2014-09-16 |
2017-10-18 |
イース チャーム リミテッド |
抗ｅｇｆｒ抗体および同抗体の使用法
|
|
US10413615B2
(en)
|
2014-11-19 |
2019-09-17 |
Immunogen, Inc. |
Process for preparing cell-binding agent-cytotoxic agent conjugates
|
|
JO3705B1
(ar)
|
2014-11-26 |
2021-01-31 |
Bayer Pharma AG |
إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
|
|
KR102407261B1
(ko)
|
2015-02-27 |
2022-07-06 |
서울대학교산학협력단 |
나노 항암제형 및 그 제조 방법
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
US11160871B2
(en)
*
|
2015-10-28 |
2021-11-02 |
Tarveda Therapeutics, Inc. |
SSTR-targeted conjugates and particles and formulations thereof
|
|
RS60237B1
(sr)
|
2015-11-24 |
2020-06-30 |
Theravance Biopharma R&D Ip Llc |
Prolekovi jak inhibitornih jedinjenja za lečenje gastorintestinalne inflamatorne bolesti
|
|
KR102498258B1
(ko)
|
2016-01-20 |
2023-02-10 |
삼성디스플레이 주식회사 |
표시 장치
|
|
US20170267727A1
(en)
|
2016-03-04 |
2017-09-21 |
Lehigh University |
Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors
|
|
EP3426301A4
(en)
|
2016-03-08 |
2019-11-06 |
Los Gatos Pharmaceuticals, Inc. |
VERBUNDNANOPARTICLES AND USES THEREOF
|
|
EP3442592A4
(en)
*
|
2016-04-13 |
2019-11-27 |
Tarveda Therapeutics, Inc. |
NEUROTENSIN RECEPTOR BINDING CONJUGATES AND FORMULATIONS THEREOF
|
|
GB201608885D0
(en)
|
2016-05-20 |
2016-07-06 |
Univ Birmingham |
Treatment
|
|
WO2017210608A1
(en)
|
2016-06-02 |
2017-12-07 |
Yale University |
Compositions and methods for targeting and treating homologous recombination-deficient tumors
|
|
EP3491007A4
(en)
*
|
2016-07-29 |
2020-04-22 |
Memorial Sloan-Kettering Cancer Center |
RADIOACTIVELY MARKED LIGANDS FOR TARGETED PET / SPECT IMAGING AND METHOD FOR THE USE THEREOF
|
|
CA3032775C
(en)
|
2016-08-16 |
2024-01-23 |
National Institute Of Advanced Industrial Science And Technology |
Malignant tumor target peptide
|
|
CA3037241A1
(en)
*
|
2016-09-22 |
2018-03-29 |
Rhode Island Council On Postsecondary Education |
Fluorescent compound comprising a fluorophore conjugated to a ph-triggered polypeptide
|
|
CA3044898C
(en)
|
2016-11-25 |
2022-04-05 |
Mabwell (shanghai) Bioscience Co., Ltd. |
Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof
|
|
WO2018118015A1
(en)
|
2016-12-19 |
2018-06-28 |
Morehouse School Of Medicine |
Compositions and methods for treating diseases by inhibiting exosome release
|
|
WO2018227132A1
(en)
|
2017-06-09 |
2018-12-13 |
Rhode Island Council On Postsecondary Education |
Linked and other ph-triggered compounds
|
|
CA3074208C
(en)
|
2017-08-31 |
2023-10-03 |
Daiichi Sankyo Company, Limited |
Novel method for producing antibody-drug conjugate
|
|
KR20200121800A
(ko)
|
2018-01-05 |
2020-10-26 |
싸이브렉사 1, 인크. |
산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
|
|
MX2020007442A
(es)
|
2018-01-12 |
2020-09-14 |
Prolynx Llc |
Protocolo para minimizar la toxicidad de dosificaciones de combinacion y agente formador de imagen para verificacion.
|
|
SG11202010496WA
(en)
|
2018-05-18 |
2020-12-30 |
Daiichi Sankyo Co Ltd |
Anti-muc1 antibody-drug conjugate
|
|
TWI851577B
(zh)
|
2018-06-07 |
2024-08-11 |
美商思進公司 |
喜樹鹼結合物
|
|
CN109232719B
(zh)
|
2018-09-21 |
2021-06-29 |
中国科学院理化技术研究所 |
一种pH响应的抗菌肽及其制备方法和应用
|
|
EP3917528A4
(en)
|
2019-01-28 |
2022-12-28 |
University of Rhode Island Board of Trustees |
Phlip® targeted delivery of potent cytotoxic compounds
|
|
MX2021011812A
(es)
|
2019-03-29 |
2021-10-22 |
Medimmune Ltd |
Compuestos y conjugados de estos.
|
|
MX2022000449A
(es)
|
2019-07-10 |
2022-04-25 |
Cybrexa 2 Inc |
Conjugados peptídicos de citotoxinas como terapéuticos.
|
|
US11555019B2
(en)
|
2019-07-10 |
2023-01-17 |
Cybrexa 3, Inc. |
Peptide conjugates of microtubule-targeting agents as therapeutics
|
|
CN116940691A
(zh)
|
2021-01-08 |
2023-10-24 |
赛博克萨2公司 |
用于制备缀合物连接部分的方法
|
|
CN117897175A
(zh)
|
2021-04-29 |
2024-04-16 |
美商斯布雷克萨二号公司 |
拓扑异构酶i抑制剂的肽缀合物的给药方案
|
|
MX2024005938A
(es)
|
2021-11-17 |
2024-08-14 |
Cybrexa 4 Inc |
Conjugados peptídicos de inhibidores de tubulina peptídica como agentes terapéuticos.
|